Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunomodulator slow-release preparation and preparation method thereof

A technology of sustained-release tablets and sustained-release layers, which is applied in the directions of pill delivery, pharmaceutical formulations, and medical preparations with inactive ingredients, etc., can solve the problems of affecting the therapeutic effect, low blood drug concentration, toxic and side effects, etc., and prolong the action time. , Simple prescription, good stability

Active Publication Date: 2014-03-05
AC PHARMA CO LTD
View PDF6 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, lenalidomide has a certain degree of toxicity, and a one-time intake of a large amount may lead to obvious toxic and side effects
Therefore, the recommended usage of REVLIMID is once a day, resulting in a lower plasma concentration of lenalidomide in the next medication, affecting the therapeutic effect
Therefore, in order to maintain a certain concentration of lenalidomide during treatment, a sustained-release dosage form is a good solution, but due to technical difficulties, there is currently no sustained-release dosage form of lenalidomide on the market

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunomodulator slow-release preparation and preparation method thereof
  • Immunomodulator slow-release preparation and preparation method thereof
  • Immunomodulator slow-release preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0136] A lenalidomide sustained-release tablet, comprising the following components (calculated in 1000 tablets):

[0137] Lenalidomide 25.00 g

[0138] Hypromellose (3000mPa·s-8000 mPa·s)

[0139] (sustained release matrix material) 200.00 g

[0140] Povidone (adhesive) 25.00 g

[0141] Microcrystalline cellulose (filler) 112.50 g

[0142] Mannitol (bulking agent) 100.00 g

[0143] Povidone (solubilizer) 25.00 g

[0144] Talc powder (glidant) 5.00 g

[0145] Magnesium stearate (lubricant) 7.50 g

[0146] Opadry II (film coating material) 15.00 g

[0147] The method for preparing the above-mentioned lenalidomide sustained-release tablet comprises the following steps:

[0148] (1) According to the prescription, lenalidomide fine powder, slow-release matrix material, adhesive, filler and solubilizer are passed through a 40-mesh sieve, and the glidant and lubricant are passed through a 80-mesh sieve;

[0149] (2) Accurately weigh lenalidomide, sustained-release matrix ma...

Embodiment 2

[0157] A lenalidomide sustained-release tablet, comprising the following components (calculated in 1000 tablets):

[0158] Lenalidomide 25.00 g

[0159] Hypromellose (12000mPa·s-21000 mPa·s)

[0160] (sustained release matrix material) 150.00 g

[0161] Pregelatinized starch (binder) 100.00 g

[0162] Calcium hydrogen phosphate (filler) 635.00 g

[0163] Povidone (solubilizer) 10.00 g

[0164] Talc powder (glidant) 50.00 g

[0165] Magnesium stearate (lubricant) 30.00 g

[0166] Opadry II (film coating material) 30.00 g

[0167] The method for preparing the above-mentioned lenalidomide sustained-release tablet is the same as that in Example 1.

[0168]

Embodiment 3

[0170] A lenalidomide sustained-release tablet, comprising the following components (calculated in 1000 tablets):

[0171] Lenalidomide 25.00 g

[0172] Carbomer (sustained release matrix material) 180.00 g

[0173] Povidone (adhesive) 15.00 g

[0174] Compressible starch (filler) 52.50 g

[0175] Hydroxypropyl-β-cyclodextrin (solubilizer) 65.00 g

[0176] Micronized silica gel (glidant) 1.50 g

[0177] Magnesium stearate (lubricant) 1.50 g

[0178] Opadry II (film coating material) 12.00 g

[0179] The method for preparing the above-mentioned lenalidomide sustained-release tablet is the same as that in Example 1.

[0180]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
viscosityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.

Description

technical field [0001] The invention relates to a sustained-release preparation and a preparation method thereof, in particular to a sustained-release tablet of an immunomodulator lenalidomide and a preparation method thereof. Background technique [0002] Lenalidomide, chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione, molecular formula C 13 h 13 N 3 o 3 , its molecular weight is 259.2606, soluble in DMSO (100mg / ml), slightly soluble in methanol, ethanol, acetonitrile and water, it needs to be micronized, form strong acid salt or add solubilizer to improve its water solubility. [0003] Lenalidomide is an antineoplastic drug developed by Celgene Biopharmaceutical Company of the United States for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). It was approved by the FDA in 2005. [0004] Lenalidomide is a representative drug of the new generation of immunomodulators, with a unique dual mechanism of action. On the one hand, l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/24A61K9/30A61K47/38A61K31/454A61P35/00A61P37/04
Inventor 刘锋赖树挺
Owner AC PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com